Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

August 31, 2011

Study Completion Date

May 31, 2013

Conditions
Kidney Cancer
Interventions
BIOLOGICAL

bevacizumab

15 mg/kg over 90 minutes every 3 weeks

Trial Locations (1)

43210

Ohio State University Medical Center, Columbus

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Paul Monk

OTHER

NCT00601926 - Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter